Clinical Trials Browser

Phase 3 × INDUSTRY × RC-18 × Clear all

NCT03016013 2024-09-26

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Phase 3 Completed

Arthritis, Rheumatoid, Lymphoma, Follicular